Company attributes
Other attributes
AsclepiX Therapeutics is a biotechnology company that is developing therapeutics for the purpose of treating retinal diseases and cancer. AsclepiX Therapeutics focuses on revolutionalizing the treatment of ocular diseases and cancer via the clinical development of therapies aimed at strengthening patients and their families throughout the globe with the freedom to live better lives.
It uses computational biology methods to identify several families of peptides that are potent regulators of vascular homeostasis. Its clinical candidates are gotten from these peptides and work through naturally existing, evolving, and self-regulating mechanisms of homeostasis that maintain humans' health and well-being.
In ophthalmology, the company focuses on the leading causes of blindness in adults: diabetic macular edema, neovascular (wet) age-related macular degeneration (wet AMD), and macular edema following retinal vein occlusion. In Oncology, it is developing treatments to activate anti-tumor immunity, inhibit metastasis, and improve efficacy when used in combination with immunotherapy and chemotherapy.
